A Study to Test a New Decongestant in Patients With Allergic Rhinitis Following a Nasal Allergen Challenge

• Status: Completed
• Trial end date: 2008-08-01
• Target enrollment: 0
• Participant gender: All

Summary

An H3 receptor antagonist should reduce the congestion associated with allergic rhinitis. A nasal allergen challenge will be given to patients to induce rhinitis symptoms and acoustic rhinometry will be used to measure the congestion.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Fexofenadine; Terfenadine

Criteria

Inclusion Criteria:

• Male or female subjects 19-55 years with allergic rhinitis requiring treatment within the previous 2 years.

• Subjects that respond to a ragweed nasal allergen challenge at screening.

Exclusion Criteria:

• History of asthma or FEV1 < 80% predicted.

• Significant concomitant disease or medications.

• Symptoms of allergic rhinitis within 2 weeks prior to screening.